Aldeyra Therapeutics Shares Rise 11% After Positive Data for

By Chris Wack


Aldeyra Therapeutics shares were up 11% to $11.61 after the company said it saw positive top-line results from its Phase 3 clinical trial of 0.25% reproxalap ophthalmic solution,... | June 15, 2023

Related Keywords

Chris Wack , Drug Administration , Dow Jones , Aldeyra Therapeutics , Nc Stock Exchange , News , Information , Press Release , Y , Chris , Back , Ldeyra , Herapeutics , Hares , Were , P , O , After , The , Company , Aid , It , Jaw , Positive , Results , Rom , Its , Hase , , Linical , Trial , F , Eproxalap , Phthalmic Aldx Us01438t1060 ,